Treatment Horizons for Triple-negative Breast Cancer

Full Article

W Yeo

Hong Kong J Radiol 2015;18:111-8

DOI: 10.12809/hkjr1515321

Triple-negative breast cancer is a distinct clinical subtype characterised by tumours that do not express oestrogen receptor, progesterone receptor, or HER-2 oncogene. Patients with triple-negative breast cancer have been reported to have a poor outcome. The mainstay of systemic treatment is chemotherapy. It has been noted that triple-negative breast cancer may be further sub-classified and one of the subclasses is the BRCA-associated tumour. In this article, systemic treatment for triple-negative breast cancer in the advanced metastatic, neoadjuvant, and adjuvant setting will be discussed. In particular, recent data in relation to the role of platinum compounds and poly (ADP-ribose) polymerase inhibitors will be reviewed.

中文摘要

三陰性乳癌的治療端倪

楊明明

三陰性乳癌雌激素受體、孕激素受體及HER2均呈陰性。三陰性乳癌患者預後較差。主要的系統治療方法為化療。三陰性乳癌的亞型可再細分，其中一亞型與BRCA基因突變相關。本文將討論轉移性三陰性乳癌的系統治療及誘導化療和輔助化療，並側重討論鉑藥及PARP抑制藥在三陰性乳癌的應用。